Vaxcyte, Inc.PCVXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank59
3Y CAGR+22.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+22.7%/yr
Quarterly compound
Percentile
P59
Within normal range
vs 3Y Ago
1.8x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.30% |
| Q3 2025 | 8.11% |
| Q2 2025 | 31.08% |
| Q1 2025 | 10.87% |
| Q4 2024 | 14.26% |
| Q3 2024 | -11.08% |
| Q2 2024 | 39.03% |
| Q1 2024 | -9.18% |
| Q4 2023 | 6.91% |
| Q3 2023 | 34.02% |
| Q2 2023 | 25.16% |
| Q1 2023 | 12.50% |
| Q4 2022 | 8.28% |
| Q3 2022 | 23.94% |
| Q2 2022 | 21.44% |
| Q1 2022 | 37.29% |
| Q4 2021 | 12.95% |
| Q3 2021 | 15.73% |
| Q2 2021 | 2.28% |
| Q1 2021 | 17.71% |
| Q4 2020 | -10.66% |
| Q3 2020 | -9.73% |
| Q2 2020 | -25.24% |
| Q1 2020 | 81.70% |
| Q4 2019 | 38.96% |
| Q3 2019 | -3.39% |
| Q2 2019 | -21.06% |
| Q1 2019 | 0.00% |